CACNA1B: Voltage-dependent N-type calcium channel subunit alpha-1B
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death.
- Drugs that act on it: 7
- Approved: 3
- In phases 1 to 3: 4
- Sponsors: 5
Who Is On It, and How Far Along
Every drug ChEMBL records acting on CACNA1B, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
- Protein or peptide
Approved3
Phase 31
Phase 23
Phase 10
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule571%
- Protein or peptide229%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Voltage-gated N-type calcium channel alpha-1B subunit blocker.| Levetiracetam | Approved | UCB | Small molecule | Blocker | — | 41 | — |
| Ziconotide | Approved | Esteve | Protein or peptide | Blocker | — | 4 | — |
| Ziconotide acetate | Approved | Esteve | Protein or peptide | Blocker | — | 0 | — |
| Ralfinamide | Phase 3 | Newron Pharmaceuticals SPA | Small molecule | Blocker | — | 0 | — |
| Z160 | Phase 2 | Zalicus | Small molecule | Blocker | — | 1 | — |
| CNV2197944 | Phase 2 | Convergence Pharmaceuticals | Small molecule | Blocker | — | 0 | — |
| Elpetrigine | Phase 2 | — | Small molecule | Blocker | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Seizure
- 0.72
- Neurodevelopmental disorder with seizures and non-epileptic hyperkinetic movements
- 0.70
- Epilepsy
- 0.61
- Bilateral tonic-clonic seizure
- 0.60
- Neuropathic pain
- 0.60
- Fibromyalgia
- 0.60
- Anxiety disorder
- 0.57
- Neuralgia
- 0.56
- Pain
- 0.56
- Movement disorder
- 0.53
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- CACNA1B
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4478, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q00975, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets